Nan-Shu Xing1, Guan-Zhi Fan1, Fei Yan1, Yi-Ping Liu1, Rong Zhang2. 1. Department of Rheumatology, The 1st Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, China. 2. Department of Rheumatology, The 1st Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, China. Electronic address: zhangrongcmu@163.com.
Abstract
OBJECTIVE: Rituximab (RTX) is widely used in the treatment of connective tissue disease (CTD) because it can target and eliminate pathogenic B cells. Interstitial lung disease (ILD) is one of the common complications of CTD; however, the clinical benefits of RTX in connective tissue disease-associated interstitial lung disease (CTD-ILD) are still controversial. This meta-analysis was performed to systematically evaluate the efficacy and safety of RTX in CTD-ILD patients. METHODS: We performed a systematic online query in PubMed, Cochrane, and Embase up to February 2020. Randomized controlled trials and observational studies on the use of RTX and conventional treatment in CTD-ILD patients were comprehensively reviewed and investigated. RESULTS: In total, 6 studies, including 242 participants, were analysed. The pooled results showed that RTX is superior to conventional treatment methods in improving forced vital capacity and modified Rodnan skin scores (MRSS) in patients with systemic sclerosis (P＜0. 05), but there was no statistically significant difference between RTX and conventional treatment method in the improvement of lung diffusion function. The risk of adverse effects declined in the RTX therapy groups compared with the conventional therapy groups in terms of infection and the blood system. CONCLUSION: The pooled results of this meta-analysis indicated that RTX is well tolerated, and RTX is able to improve or stabilize pulmonary function in CTD-ILD patients.
OBJECTIVE:Rituximab (RTX) is widely used in the treatment of connective tissue disease (CTD) because it can target and eliminate pathogenic B cells. Interstitial lung disease (ILD) is one of the common complications of CTD; however, the clinical benefits of RTX in connective tissue disease-associated interstitial lung disease (CTD-ILD) are still controversial. This meta-analysis was performed to systematically evaluate the efficacy and safety of RTX in CTD-ILDpatients. METHODS: We performed a systematic online query in PubMed, Cochrane, and Embase up to February 2020. Randomized controlled trials and observational studies on the use of RTX and conventional treatment in CTD-ILDpatients were comprehensively reviewed and investigated. RESULTS: In total, 6 studies, including 242 participants, were analysed. The pooled results showed that RTX is superior to conventional treatment methods in improving forced vital capacity and modified Rodnan skin scores (MRSS) in patients with systemic sclerosis (P＜0. 05), but there was no statistically significant difference between RTX and conventional treatment method in the improvement of lung diffusion function. The risk of adverse effects declined in the RTX therapy groups compared with the conventional therapy groups in terms of infection and the blood system. CONCLUSION: The pooled results of this meta-analysis indicated that RTX is well tolerated, and RTX is able to improve or stabilize pulmonary function in CTD-ILDpatients.
Authors: Natalia Mena-Vázquez; Rocío Redondo-Rodríguez; Marta Rojas-Gimenez; Carmen María Romero-Barco; Sara Manrique-Arija; Rafaela Ortega-Castro; Ana Hidalgo Conde; Rocío Arnedo Díez de Los Ríos; Eva Cabrera César; Francisco Espildora; María Carmen Aguilar-Hurtado; Isabel Añón-Oñate; Lorena Pérez-Albaladejo; Manuel Abarca-Costalago; Inmaculada Ureña-Garnica; Maria Luisa Velloso-Feijoo; Maria Victoria Irigoyen-Oyarzábal; Antonio Fernández-Nebro Journal: J Clin Med Date: 2022-02-10 Impact factor: 4.241